On Friday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) opened higher 0.21% from the last session, before settling in for the closing price of $33.94. Price fluctuations for IONS have ranged from $33.33 to $54.44 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 13.97% annually for the last half of the decade. Company’s average yearly earnings per share was noted -34.59% at the time writing. With a float of $145.54 million, this company’s outstanding shares have now reached $157.90 million.
In an organization with 927 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.3%, operating margin of -46.12%, and the pretax margin is -44.3%.
Ionis Pharmaceuticals Inc (IONS) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ionis Pharmaceuticals Inc is 7.83%, while institutional ownership is 97.99%. The most recent insider transaction that took place on Nov 12 ’24, was worth 45,278. In this transaction EVP Research of this company sold 1,194 shares at a rate of $37.92, taking the stock ownership to the 33,713 shares. Before that another transaction happened on Nov 12 ’24, when Company’s Chief Executive Officer sold 6,630 for $38.05, making the entire transaction worth $252,294. This insider now owns 167,393 shares in total.
Ionis Pharmaceuticals Inc (IONS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -34.59% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Check out the current performance indicators for Ionis Pharmaceuticals Inc (IONS). In the past quarter, the stock posted a quick ratio of 8.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.44, a number that is poised to hit -1.10 in the next quarter and is forecasted to reach -3.43 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Let’s dig in a bit further. During the last 5-days, its volume was 1.97 million. That was better than the volume of 1.33 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 17.43%. Additionally, its Average True Range was 1.36.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 3.58%, which indicates a significant decrease from 10.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.47% in the past 14 days, which was higher than the 40.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $38.71, while its 200-day Moving Average is $42.81. However, in the short run, Ionis Pharmaceuticals Inc’s stock first resistance to watch stands at $34.54. Second resistance stands at $35.07. The third major resistance level sits at $35.38. If the price goes on to break the first support level at $33.70, it is likely to go to the next support level at $33.39. The third support level lies at $32.86 if the price breaches the second support level.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats
There are currently 157,897K shares outstanding in the company with a market cap of 5.38 billion. Presently, the company’s annual sales total 787,650 K according to its annual income of -366,290 K. Last quarter, the company’s sales amounted to 133,810 K and its income totaled -140,480 K.
